Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)

Main Article Content

Karl Lewis
Katty Peris
Aleksandar Sekulic
Alexander Stratigos
Lara Dunn
Zeynep Eroglu
Anne Lynn Chang
Michael Migden
Siyu Li
Suk-Young Yoo
Kosalai Mohan
Ebony Coates
Emmanuel Okoye
Jean-Francois Baurain
Oliver Bechter
Axel Hauschild
Marcus Butler
Leonel Hernandez-Aya
Lisa Licitra
Rogerio Neves
Emily Ruiz
Frank Seebach
Israel Lowy
Timothy Bowler
Matthew Fury

Keywords

Metastatic Basal Cell Carcinoma, mBCC, Biologic, Cemiplimab, Hedgehog Inhibitor, HHI

Abstract

Abstract not available.

References

1. Puig S et al. Clin Transl Oncol. 2015;17:497–503.

2. Wu S et al. Am J Epidemiol. 2013;178:890–897.

3. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

4. Murphy AJ et al. Proc Natl Acad Sci USA. 2014;111:5153–5158.

5. Macdonald LE et al. Proc Natl Acad Sci USA. 2014;111:5147–5152.

6. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

7. Sezer A et al. Poster presented at European Society of Medical Oncology (ESMO) Virtual Congress 2020. September 19–21, 2020: LBA52.

8. Migden MR et al. N Engl J Med. 2018;379:341–351.

9. Stratigos A et al. Poster presented at ESMO Virtual Congress 2020. September 19–21, 2020: LBA47.

Most read articles by the same author(s)

1 2 > >>